Harvey I Pass, MD Professor of Surgery and Cardiothoracic Surgery Director, Division of Thoracic Surgery NYU Langone Medical Center New York, New York
	Click here to download entire interview
Track 1	Lobectomy versus segmental resection for non-small cell lung cancer (NSCLC)
Track 2	Impairment of cellular immune function and type of surgery
Track 3	Role of the surgeon in translational research
Track 4	Use of biomarker analyses in lung cancer
Track 5	Genomic tests to determine prognosis in lung cancer
Track 6	Endobronchial ultrasound with transbronchial needle aspiration (EBUS-TBNA) for restaging NSCLC in the mediastinum
Track 7	Cetuximab in combination with chemoradiation therapy for Stage IIIA/B NSCLC
Track 8	Clinical use of EBUS-TBNA
Track 9	National Mesothelioma Virtual Tumor Bank
Track 10	Developing a new staging system for mesothelioma
Track 11	Stereotactic body radiation therapy (SBRT) for lung cancer
Track 12	Case Discussion: An 82-year-old woman, who is a nonsmoker, underwent video-assisted thoracoscopic surgery (VATS) for an invasive adenocarcinoma with an EGFR mutation
Track 13	Clinical research on the use of adjuvant erlotinib for patients with NSCLC and an EGFR mutation
Track 14	Resection of pulmonary metastases associated with nonlung primary cancer
Track 15	Case Discussion: A 57-year-old man, who is a nonsmoker, was treated with chemoradiation followed by surgery and consolidation docetaxel for a left hilar mass and a lymph node metastasis
Track 16	Excision repair cross-complementation group 1 (ERCC1) and ribonucleotide reductase subunit M1 (RRM1) as predictors of chemotherapy resistance
Track 17	ECOG-E1505: A Phase III randomized trial of adjuvant chemotherapy with or without bevacizumab for patients with completely resected Stage IB (>=4 cm) to IIIA NSCLC

Jeffrey A Engelman, MD, PhD Director of Lung Cancer Research Massachusetts General Hospital Assistant Professor of Medicine Harvard Medical School Boston, Massachusetts
	Click here to download entire interview
Track 1	Oncogene addiction hypothesis
Track 2	Role of EGFR mutations in the development of lung cancer
Track 3	Mechanisms of resistance to tyrosine kinase inhibitors (TKIs)
Track 4	TKIs: Dose selection and correlation between rash and efficacy
Track 5	Benefits associated with TKIs in patients without EGFR mutations
Track 6	Clinical use of EGFR mutation testing
Track 7	Incidence of EGFR and K-ras mutations in smokers and nonsmokers
Track 8	Clinical research on cetuximab in NSCLC
Track 9	NSCLC as a biologically heterogeneous disease
Track 10	Normalization of vasculature by bevacizumab
Track 11	Anaplastic lymphoma kinase (ALK) translocations in lung cancer
Track 12	Case Discussion: A 45-year-old woman who is a nonsmoker with metastatic adenocarcinoma and an ALK translocation
Track 13	Frequency of and testing for ALK translocations in NSCLC
Track 14	TKI-associated toxicities
Track 15	Case Discussion: A 54-year-old woman with a metastatic adenocarcinoma and an exon 19 deletion who received erlotinib for 18 months
Track 16	Continuation of erlotinib upon disease progression
Track 17	Erlotinib for the treatment of CNS metastases

Ritsuko Komaki, MD Professor of Radiation Oncology Gloria Lupton Tennison Endowed Professor in Lung Cancer Research The University of Texas MD Anderson Cancer Center Houston, Texas
	Click here to download entire interview
Track 1	Case Discussion: A 76-year-old man treated with SBRT for a second squamous cell carcinoma
Track 2	Risks and benefits associated with SBRT
Track 3	Randomized trial evaluating SBRT versus surgery
Track 4	Clinical use of SBRT
Track 5	Case Discussion: A 51-year-old man with limited-stage small cell lung cancer (SCLC) and Eaton-Lambert syndrome who had a complete response to chemoradiation therapy
Track 6	Neurocognitive impairment associated with prophylactic cranial irradiation
Track 7	Case Discussion: A 62-year-old man with Stage IIIA NSCLC who was treated with cetuximab in combination with chemoradiation therapy
Track 8	RTOG-0324: A Phase II trial of cetuximab in combination with chemoradiation therapy for Stage IIIA/B NSCLC
Track 9	Clinical use of cetuximab in combination with chemoradiation therapy
Track 10	Use of tumor histology and biomarkers in the selection of EGFR or VEGF inhibitors for the treatment of solid tumors

Renato G Martins, MD, MPH Associate Professor Medical Director of Outpatient Services Seattle Cancer Care Alliance Medical Director of the Thoracic/ Head and Neck Cancer Program University of Washington Seattle, Washington
	Click here to download entire interview
Track 1	Case Discussion: A 58-year-old man who is a former smoker with a Stage II adenocarcinoma treated with adjuvant cisplatin/pemetrexed
Track 2	Tissue biomarkers as predictors of benefit from adjuvant chemotherapy for NSCLC
Track 3	Tumor histology as a predictor of benefit from adjuvant chemotherapy for NSCLC
Track 4	Monitoring patients after completion of adjuvant therapy for NSCLC
Track 5	Clinical use of neoadjuvant therapy for NSCLC
Track 6	Role of adjuvant chemotherapy for Stage IB NSCLC
Track 7	Ongoing adjuvant trials with bevacizumab or erlotinib
Track 8	Clinical use of adjuvant erlotinib in patients with NSCLC and EGFR mutations
Web track 1	Case Discussion: A 64-year-old woman and former smoker with a biopsy-confirmed TTF1-positive adenocarcinoma of the lumbar spine from non-small cell lung cancer (NSCLC)
Web track 2	Perspective on the FLEX trial results of cisplatin/vinorelbine with or without cetuximab as first-line therapy for patients with advanced NSCLC
Web track 3	Rationale for cisplatin/pemetrexed with or without bevacizumab as first-line therapy for patients with nonsquamous cell NSCLC
Web track 4	Case Discussion: A 66-year-old woman, a nonsmoker, with biopsy-proven hepatic metastases from adenocarcinoma of the lung with EGFR exon 19 deletion who demonstrated a sustained complete response with erlotinib
Web track 5	Use of erlotinib for patients with NSCLC and suspected EGFR mutations
Web track 6	Detection of mutations in EGFR in circulating lung cancer cells
Web track 7	T790M mutation-associated resistance to EGFR inhibition